Search the Newsreel

GOVX: GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply

GeoVax Labs, Inc. (GOVX) aims to disrupt the global MVA vaccine market with its GEO-MVA program, addressing a $1.3 billion demand through a fast-tracked regulatory process and scalable U.S. manufacturing. Additionally, the company is advancing Gedeptin® as a novel therapy for solid tumors, supported …

GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway

GeoVax Labs Inc. is preparing to initiate a pivotal phase 3 trial for its GEO-MVA mpox and smallpox vaccine candidate by the end of 2024, following an expedited regulatory pathway granted by the European Medicines Agency (EMA). The EMA waived phase 1 and 2 …

GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase

GeoVax is highlighting its Gedeptin(R) therapy as a tumor-priming strategy following the FDA's accelerated approval of Replimune's intratumoral therapy TUDRIQEV in combination with nivolumab. GeoVax believes this approval reinforces the paradigm that local tumor destruction can enhance immune responses, an area where Gedeptin, a …

Jane Street Group discloses 4.3% GeoVax Labs (GOVX) ownership in updated 13G

Jane Street Group, LLC, along with its subsidiaries Jane Street Capital, LLC and Jane Street Global Trading, LLC, has filed an amended Schedule 13G disclosing a 4.3% beneficial ownership in GeoVax Labs, Inc. (GOVX). This stake amounts to 315,275 shares of common stock, with …

GeoVax Labs Inc (GOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates

GeoVax Labs Inc (GOVX) has an earnings forecast score of 8.00, ranking 171 out of 387 in its industry. Analysts have set an average price target of $8.50, with a significant upside potential of over 10000% based on two analysts' Buy recommendations. The company's …

GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio

GeoVax Labs, Inc. highlighted new independent research that supports broader vaccine strategies for filoviruses, emphasizing the potential of its MVA-based vaccine portfolio. The study indicates that immune responses from licensed Ebola vaccines might extend to related ebolavirus species, reinforcing GeoVax's approach to developing broadly …

GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of GeoVax Labs Inc (GOVX), listing its major individual shareholders and their respective proportions, as well as categorizing shareholder types. It also provides a historical overview of institutional shareholding, including the number of institutions, shares held, and proportional …

Geovax Labs Market Sentiment

This article provides an overview of Geovax Labs (GOVX) market sentiment, including analyst consensus, short interest, options flow, and insider activity. Six analysts have a "Buy" consensus with an average price target of $12, while short interest is 1.2% and declining. The report also …

GeoVax Labs Inc (GOVX) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of GeoVax Labs Inc (GOVX), assigning it a TradingKey financial score of 6.30, which ranks 261 out of 384 in its industry. While its financial status is stable, the company shows low operating efficiency. The latest quarterly revenue …

Geovax Labs Risk Profile Appears Stable, But Investors Should Watch for Emerging SEC-Disclosed Pressures

Geovax Labs, Inc. (GOVX) has disclosed a new risk in the "Costs" category, though its overall risk profile appears stable without material changes. Investors are advised to monitor future SEC filings for new disclosures under Item 1A of Form 10-K or forward-looking statements, which …

GeoVax Labs Inc (GOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for GeoVax Labs Inc (GOVX), noting its current risk score of 1.47, which ranks it 292 out of 384 in the Biotechnology & Medical Research industry. The company's beta of 3.66 indicates high volatility relative to the S&P …

GeoVax Labs Inc (GOVX) Income Statement

This article provides the quarterly and annual income statements for GeoVax Labs Inc (GOVX), detailing key financial metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. It also includes an FAQ section explaining how to read the income statement …

GeoVax Labs Inc (GOVX) Cash Flow

This article provides a detailed historical cash flow statement for GeoVax Labs Inc (GOVX), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures along with year-over-year percentage changes. The article also includes FAQs explaining key cash flow terms …

GeoVax Labs reports Q2 net loss $4.43M, cash ~$3.1M; advances GEO‑MVA pivotal study

GeoVax Labs reported a Q2 2026 net loss of $4.43 million, with cash and cash equivalents around $3.1 million. The company is advancing its GEO-MVA immunobridging study and its Gedeptin immuno-oncology program after discontinuing its COVID-19 candidate to prioritize resources. Revenue ceased due to …

GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update

GeoVax reported a net loss of $4.4 million for Q2 2026, or $0.97 per share, and provided an update on its lead programs. The company is advancing its GEO-MVA vaccine candidate towards a pivotal immunobridging study and continuing development of its Gedeptin® immuno-oncology program, …

GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary

GeoVax Labs, Inc. reported a 10-Q summary for 2026, showing no revenue but a reduced net loss compared to the previous year. The company is re-focusing on its lead vaccine and oncolytic programs, including advancing GEO-MVA to Phase 3 and developing Gedeptin. Funding currently …

GeoVax Labs (GOVX) narrows loss but warns on cash runway and Nasdaq risk

GeoVax Labs (GOVX) Earnings Date and Reports 2026

GEOVAX LABS ($GOVX) Releases Q2 2026 Earnings

GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of GeoVax Labs Inc (GOVX) stock information, including its current trading price, market capitalization, and historical dividend payments. It highlights that the company has distributed $0.00 in dividends over the past five years. The document also lists several stock …

GeoVax Labs, Inc. Revenue Breakdown – NASDAQ:GOVX

GeoVax Labs, Inc. (NASDAQ: GOVX) generated $2.50 million USD in revenue last year, primarily from its Vaccines and Immunotherapies segment, which accounted for $2.49 million USD. This represents a decrease from the previous year's total revenue of $3.95 million USD. The majority of the …

GOVX|GeoVax Labs Inc|Price:0.733|Chg%:-0.107

GeoVax Labs Inc (GOVX) is a clinical-stage biotechnology company developing vaccines for infectious diseases and therapies for solid tumor cancers. Despite a recent weak stock performance, analysts rate the stock as "Buy" with a high price target, reflecting strong fundamentals and growth potential. The …

GeoVax Labs Inc (GOVX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for GeoVax Labs Inc (GOVX), highlighting its current valuation score, market capitalization, and stock price performance. It notes that key valuation ratios such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. The analysis …